当前位置: X-MOL 学术Allergol. Immunopathol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Immunogenicity of a new allergoid from Felis domesticus.
Allergologia et Immunopathologia ( IF 2.5 ) Pub Date : 2020-05-20 , DOI: 10.1016/j.aller.2020.02.008
J P Sola González 1 , E Bravo Hernández 1 , A Cerezo Abellán 1 , M Peñalver-Mellado 1
Affiliation  

Background

The chemical modification of allergens with glutaraldehyde improves safety while maintaining clinical efficacy, which permits the administration of higher doses of immunotherapy, reducing the risk of adverse reactions. The aim of this study is to evaluate the immunogenic capacity of a new cat dander polymer by immunizing mice and quantifying immunoglobulins in serum, in comparison with the non-modified allergen.

Methods

The study consists of the immunization of three mice groups with the polymerized and the native extract, together with a negative control group. The immunoglobulin levels in serum have been measured by indirect ELISA. By means of the non-parametric Mann–Whitney U test, it was determined if there were significant differences in the values of specific antibodies between groups.

Results

The group immunized with the allergoid showed significantly higher specific IgG and IgG1 values to dander allergens and specific IgG to the major allergen Fel d 1, while there were no significant changes in IgG2a and IgE values. These results could be due to a higher immunization dose. The vaccine formulation was based on the optimal defined dose for clinical efficacy of allergen immunotherapy.

Conclusions

This preclinical study carried out with the present assay has established that the allergoid of cat dander extract, as designed for its optimal use in allergen immunotherapy, produces a higher specific IgG than the native extract, in addition to showing significantly higher specific IgG1 levels, evidencing a greater effectiveness in immunization.



中文翻译:

来自家猫的新过敏原的免疫原性。

背景

用戊二醛对过敏原进行化学修饰提高了安全性,同时保持了临床疗效,这允许给予更高剂量的免疫治疗,降低不良反应的风险。本研究的目的是通过免疫小鼠和定量免疫球蛋白来评估一种新的猫皮屑聚合物的免疫原性能力。 在血清中,与未修饰的过敏原相比。

方法

该研究包括用聚合提取物和天然提取物免疫三个小鼠组以及一个阴性对照组。血清中的免疫球蛋白水平已通过间接 ELISA 测量。通过非参数 Mann-Whitney U检验,确定组间特异性抗体的值是否存在显着差异。

结果

用过敏原免疫的组对皮屑过敏原的特异性 IgG 和 IgG1 值以及对主要过敏原 Fel d 1 的特异性 IgG 显示出显着更高的值,而 IgG2a 和 IgE 值没有显着变化。这些结果可能是由于更高的免疫剂量。疫苗配方基于过敏原免疫疗法临床疗效的最佳确定剂量。

结论

使用本试验进行的临床前研究已经确定,猫皮屑提取物的变应原,设计用于过敏原免疫治疗的最佳用途,产生比天然提取物更高的特异性 IgG,除了显示出显着更高的特异性 IgG1 水平,证明免疫效果更好。

更新日期:2020-05-20
down
wechat
bug